Intracalvariosseous injection: an approach for central nervous system drug delivery through skull bone marrow with a preclinical research in strokeResearch in context
Summary: Background: Central nervous system (CNS) accessibility constitutes a major hurdle for drug development to treat neurological diseases. Existing drug delivery methods rely on breaking the blood-brain barrier (BBB) for drugs to penetrate the CNS. Researchers have discovered natural microchan...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S235239642500012X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576487939637248 |
|---|---|
| author | Wenqian Liu Mo Yang Nanxing Wang Xiangrong Liu Chaoyu Wang Kaibin Shi Fu-Dong Shi Yuesong Pan Mingjun Zhang Zhiwei Sun Yongjun Wang Yilong Wang |
| author_facet | Wenqian Liu Mo Yang Nanxing Wang Xiangrong Liu Chaoyu Wang Kaibin Shi Fu-Dong Shi Yuesong Pan Mingjun Zhang Zhiwei Sun Yongjun Wang Yilong Wang |
| author_sort | Wenqian Liu |
| collection | DOAJ |
| description | Summary: Background: Central nervous system (CNS) accessibility constitutes a major hurdle for drug development to treat neurological diseases. Existing drug delivery methods rely on breaking the blood-brain barrier (BBB) for drugs to penetrate the CNS. Researchers have discovered natural microchannels between the skull bone marrow and the dura mater, providing a pathway for drug delivery through the skull bone marrow. However, there has been no research on the feasibility, safety, and efficacy of this delivery method for drug treatment of stroke. Methods: We used a microporous method for intracalvariosseous (ICO) injection to deliver drugs directly into brain parenchyma through skull bone marrow. Safety of ICO was assessed by monitoring changes in skull and peripheral blood neutrophil counts, and FITC-dextran extravasation across the BBB. Drug delivery pathways were observed through transparent skull-dura mater-brain tissue. In a rodent stroke model, NA-1 or Y-3 neuroprotective agents were administered via ICO to evaluate safety and efficacy by assessing neurological deficits, infarct size, neuroinflammatory factors, neuronal apoptosis, and liver/kidney function. Drug concentration in tissues was measured using fluorescence tracing and high-performance liquid chromatography to gauge ICO delivery efficiency. Findings: ICO injection delivers drugs to the brain parenchyma through microchannels between the skull bone marrow and the dura mater, offering higher delivery efficiency than intravenous injection. After ICO injection, there were no changes in neutrophil counts in the skull bone marrow and peripheral blood, and the amount of FITC-dextran passing through the BBB remained unchanged. This confirmed that ICO injection does not cause skull infection or break BBB, which suggested ICO injection is safe and feasible. In the treatment of stroke with neuroprotective agents, although the drug dosage of ICO injection was lower than intravenous injection, drug accumulation in the brain increased after ICO injection, which helped repair nerve damage, reduce neuronal apoptosis, and decrease the expression of inflammatory factors. Interpretation: ICO injection is a central nervous system drug delivery method that utilizes natural microchannels between the skull and dura mater for efficient drug delivery. Our results assessed the feasibility and safety of ICO injection at the preclinical level and evaluated its efficacy in animal models of stroke. The findings provided a foundation for the clinical translation of ICO injection. Funding: This study was supported by The National Natural Science Foundation of China (No. 82425101); Beijing Municipal Science & Technology Commission (No. Z231100004823036); Capital's Funds for Health Improvement and Research (2022-2-2045); National Key Research & Development Program of China (2022YFF1501500, 2022YFF1501501, 2022YFF1501502, 2022YFF1501503, 2022YFF1501504, 2022YFF1501505). |
| format | Article |
| id | doaj-art-85111801b2f84a3f8c29ac859de769ac |
| institution | Kabale University |
| issn | 2352-3964 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EBioMedicine |
| spelling | doaj-art-85111801b2f84a3f8c29ac859de769ac2025-01-31T05:11:52ZengElsevierEBioMedicine2352-39642025-02-01112105568Intracalvariosseous injection: an approach for central nervous system drug delivery through skull bone marrow with a preclinical research in strokeResearch in contextWenqian Liu0Mo Yang1Nanxing Wang2Xiangrong Liu3Chaoyu Wang4Kaibin Shi5Fu-Dong Shi6Yuesong Pan7Mingjun Zhang8Zhiwei Sun9Yongjun Wang10Yilong Wang11Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaDepartment of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, ChinaLaboratory for Clinical Medicine, Capital Medical University, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Chinese Institute for Brain Research, Beijing, China; National Center for Neurological Disorders, Beijing, China; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Beijing Laboratory of Oral Health, Capital Medical University, Beijing, China; Laboratory for Clinical Medicine, Capital Medical University, Beijing, China; Corresponding author. No. 119 South 4th Ring West Road, Fengtai District, Beijing, 100070, China.Summary: Background: Central nervous system (CNS) accessibility constitutes a major hurdle for drug development to treat neurological diseases. Existing drug delivery methods rely on breaking the blood-brain barrier (BBB) for drugs to penetrate the CNS. Researchers have discovered natural microchannels between the skull bone marrow and the dura mater, providing a pathway for drug delivery through the skull bone marrow. However, there has been no research on the feasibility, safety, and efficacy of this delivery method for drug treatment of stroke. Methods: We used a microporous method for intracalvariosseous (ICO) injection to deliver drugs directly into brain parenchyma through skull bone marrow. Safety of ICO was assessed by monitoring changes in skull and peripheral blood neutrophil counts, and FITC-dextran extravasation across the BBB. Drug delivery pathways were observed through transparent skull-dura mater-brain tissue. In a rodent stroke model, NA-1 or Y-3 neuroprotective agents were administered via ICO to evaluate safety and efficacy by assessing neurological deficits, infarct size, neuroinflammatory factors, neuronal apoptosis, and liver/kidney function. Drug concentration in tissues was measured using fluorescence tracing and high-performance liquid chromatography to gauge ICO delivery efficiency. Findings: ICO injection delivers drugs to the brain parenchyma through microchannels between the skull bone marrow and the dura mater, offering higher delivery efficiency than intravenous injection. After ICO injection, there were no changes in neutrophil counts in the skull bone marrow and peripheral blood, and the amount of FITC-dextran passing through the BBB remained unchanged. This confirmed that ICO injection does not cause skull infection or break BBB, which suggested ICO injection is safe and feasible. In the treatment of stroke with neuroprotective agents, although the drug dosage of ICO injection was lower than intravenous injection, drug accumulation in the brain increased after ICO injection, which helped repair nerve damage, reduce neuronal apoptosis, and decrease the expression of inflammatory factors. Interpretation: ICO injection is a central nervous system drug delivery method that utilizes natural microchannels between the skull and dura mater for efficient drug delivery. Our results assessed the feasibility and safety of ICO injection at the preclinical level and evaluated its efficacy in animal models of stroke. The findings provided a foundation for the clinical translation of ICO injection. Funding: This study was supported by The National Natural Science Foundation of China (No. 82425101); Beijing Municipal Science & Technology Commission (No. Z231100004823036); Capital's Funds for Health Improvement and Research (2022-2-2045); National Key Research & Development Program of China (2022YFF1501500, 2022YFF1501501, 2022YFF1501502, 2022YFF1501503, 2022YFF1501504, 2022YFF1501505).http://www.sciencedirect.com/science/article/pii/S235239642500012XDrug deliveryBlood-brain-barrierSkull bone marrowMicrochannelsStroke |
| spellingShingle | Wenqian Liu Mo Yang Nanxing Wang Xiangrong Liu Chaoyu Wang Kaibin Shi Fu-Dong Shi Yuesong Pan Mingjun Zhang Zhiwei Sun Yongjun Wang Yilong Wang Intracalvariosseous injection: an approach for central nervous system drug delivery through skull bone marrow with a preclinical research in strokeResearch in context EBioMedicine Drug delivery Blood-brain-barrier Skull bone marrow Microchannels Stroke |
| title | Intracalvariosseous injection: an approach for central nervous system drug delivery through skull bone marrow with a preclinical research in strokeResearch in context |
| title_full | Intracalvariosseous injection: an approach for central nervous system drug delivery through skull bone marrow with a preclinical research in strokeResearch in context |
| title_fullStr | Intracalvariosseous injection: an approach for central nervous system drug delivery through skull bone marrow with a preclinical research in strokeResearch in context |
| title_full_unstemmed | Intracalvariosseous injection: an approach for central nervous system drug delivery through skull bone marrow with a preclinical research in strokeResearch in context |
| title_short | Intracalvariosseous injection: an approach for central nervous system drug delivery through skull bone marrow with a preclinical research in strokeResearch in context |
| title_sort | intracalvariosseous injection an approach for central nervous system drug delivery through skull bone marrow with a preclinical research in strokeresearch in context |
| topic | Drug delivery Blood-brain-barrier Skull bone marrow Microchannels Stroke |
| url | http://www.sciencedirect.com/science/article/pii/S235239642500012X |
| work_keys_str_mv | AT wenqianliu intracalvariosseousinjectionanapproachforcentralnervoussystemdrugdeliverythroughskullbonemarrowwithapreclinicalresearchinstrokeresearchincontext AT moyang intracalvariosseousinjectionanapproachforcentralnervoussystemdrugdeliverythroughskullbonemarrowwithapreclinicalresearchinstrokeresearchincontext AT nanxingwang intracalvariosseousinjectionanapproachforcentralnervoussystemdrugdeliverythroughskullbonemarrowwithapreclinicalresearchinstrokeresearchincontext AT xiangrongliu intracalvariosseousinjectionanapproachforcentralnervoussystemdrugdeliverythroughskullbonemarrowwithapreclinicalresearchinstrokeresearchincontext AT chaoyuwang intracalvariosseousinjectionanapproachforcentralnervoussystemdrugdeliverythroughskullbonemarrowwithapreclinicalresearchinstrokeresearchincontext AT kaibinshi intracalvariosseousinjectionanapproachforcentralnervoussystemdrugdeliverythroughskullbonemarrowwithapreclinicalresearchinstrokeresearchincontext AT fudongshi intracalvariosseousinjectionanapproachforcentralnervoussystemdrugdeliverythroughskullbonemarrowwithapreclinicalresearchinstrokeresearchincontext AT yuesongpan intracalvariosseousinjectionanapproachforcentralnervoussystemdrugdeliverythroughskullbonemarrowwithapreclinicalresearchinstrokeresearchincontext AT mingjunzhang intracalvariosseousinjectionanapproachforcentralnervoussystemdrugdeliverythroughskullbonemarrowwithapreclinicalresearchinstrokeresearchincontext AT zhiweisun intracalvariosseousinjectionanapproachforcentralnervoussystemdrugdeliverythroughskullbonemarrowwithapreclinicalresearchinstrokeresearchincontext AT yongjunwang intracalvariosseousinjectionanapproachforcentralnervoussystemdrugdeliverythroughskullbonemarrowwithapreclinicalresearchinstrokeresearchincontext AT yilongwang intracalvariosseousinjectionanapproachforcentralnervoussystemdrugdeliverythroughskullbonemarrowwithapreclinicalresearchinstrokeresearchincontext |